Bio-Techne Corp
A maker of the proteins, antibodies, and lab instruments that scientists use to study cells and diagnose disease, Bio-Techne sells brands like R&D Systems and ProteinSimple to researchers worldwide. It began in 1976 in Minneapolis as R&D Systems, making controls to verify blood-analysis machines, and rebranded as Bio-Techne in 2014 — a name blending "bio" with the Greek word "techne," meaning art or craft. Its first product, launched in 1977, was a platelet-rich-plasma control.
Granted 400.0K · Sold 187.5K
Granted 1.72M · Bought 200 · Sold 251.8K
Sold 57.6K
Granted 668.8K · Sold 163.8K
Granted 67.0K · Bought 2.4K · Sold 73.0K
Granted 232.8K · Sold 17.2K
Granted 90.4K · Sold 34.8K
Granted 87.2K · Sold 73.0K
Granted 108.4K · Bought 2.8K · Sold 97.0K
Granted 83.8K · Sold 54.7K
Granted 21.1K · Sold 8.5K
Granted 86.3K · Sold 79.0K
Granted 25.8K
Granted 12.4K · Sold 5.0K
Granted 7.4K
Granted 6.1K
Granted 19.5K · Sold 14.2K
Granted 5.7K
Granted 34.7K · Sold 26.5K
Granted 11.9K
Granted 16.9K
Granted 1.4K
Granted 1.6K
Granted 1.4K
Granted 12.9K · Sold 11.8K
Granted 2.1K
Granted 105.7K · Sold 102.3K
Granted 81.5K · Sold 121.1K
Granted 1.7K
Sold 524
Granted 19.0K · Sold 18.1K
Granted 3.6K · Sold 3.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Oland Thomas ECEO, President, Director · 15 transactions | — | 1.54Mas of Dec 2011 | 400.0K | — | 187.5K |
| Kummeth Charles R.Chief Executive Officer, Director · 98 transactions | — | 1.53Mas of Aug 2023 | 1.72M | 200 | 251.8K |
| Tsang MonicaVP of Research · 2 transactions | — | 173.3Kas of May 2007 | — | — | 57.6K |
| Hippel JamesCFO · 106 transactions | — | 153.7K | 668.8K | — | 163.8K |
| Oconnell Howard VDirector · 38 transactions | — | 142.0Kas of Feb 2015 | 67.0K | 2.4K | 73.0K |
| Kelderman KimChief Executive Officer, Director · 43 transactions | — | 89.8K | 232.8K | — | 17.2K |
| Higgins John LDirector · 43 transactions | — | 66.9K | 90.4K | — | 34.8K |
| Furlow Brenda S.SVP - GENERAL COUNSEL · 63 transactions | — | 52.0Kas of Dec 2022 | 87.2K | — | 73.0K |
| Baumgartner Robert VDirector · 60 transactions | — | 46.5K | 108.4K | 2.8K | 97.0K |
| Nusse RoelandDirector · 27 transactions | — | 44.6Kas of Aug 2025 | 83.8K | — | 54.7K |
| Veronneau MarcelSVP - Clinical Controls · 21 transactions | — | 41.8Kas of Jun 2015 | 21.1K | — | 8.5K |
| Steer Randolph CDirector · 41 transactions | — | 24.2Kas of Oct 2023 | 86.3K | — | 79.0K |
| Geist WilliamPRESIDENT, PROTEIN SCIENCES · 9 transactions | — | 20.5K | 25.8K | — | — |
| Seth AlpnaDirector · 13 transactions | — | 15.4K | 12.4K | — | 5.0K |
| Keegan Joseph DDirector · 9 transactions | — | 15.4K | 7.4K | — | — |
| Vessey RupertDirector · 7 transactions | — | 11.0K | 6.1K | — | — |
| Wiens Harold JDirector · 19 transactions | — | 8.8Kas of May 2020 | 19.5K | — | 14.2K |
| Bushman Julie LDirector · 7 transactions | — | 8.8K | 5.7K | — | — |
| Dinarello Charles ADirector · 19 transactions | — | 8.2Kas of Aug 2018 | 34.7K | — | 26.5K |
| McManus MatthewPresident - Diag & Spatial Bio · 6 transactions | — | 7.7K | 11.9K | — | — |
| Bohnen ShaneSVP - General Counsel · 12 transactions | — | 7.2K | 16.9K | — | — |
| Crouse Steven C.President - Diag & Spatial Bi · 4 transactions | — | 6.8K | 1.4K | — | — |
| Klimovsky Judith V.Director · 1 transaction | — | 3.8K | 1.6K | — | — |
| Melsen Gregory JCEO · 2 transactions | — | 3.3Kas of Aug 2013 | 1.4K | — | — |
| Herr Amy E.Director · 13 transactions | — | 2.9K | 12.9K | — | 11.8K |
| Klimovsky Judith VDirector · 2 transactions | — | 2.1Kas of Oct 2024 | 2.1K | — | — |
| Eansor Norman DavidPresident-Protein Sciences · 51 transactions | — | 2.1Kas of Nov 2021 | 105.7K | — | 102.3K |
| Lucas Roger CDirector · 51 transactions | — | 1.9Kas of Oct 2017 | 81.5K | — | 121.1K |
| Gavin Robert M.Senior V.P. Protein Platforms · 1 transaction | — | 1.7Kas of Oct 2017 | 1.7K | — | — |
| Gould Kevin SSVP Clinical Controls · 3 transactions | — | 1.4Kas of Oct 2017 | — | — | 524 |
| Holbrook Karen ADirector · 13 transactions | — | 914as of Sep 2017 | 19.0K | — | 18.1K |
| Reagan Kevin JSenior VP - Biotech · 4 transactions | — | 0as of Dec 2014 | 3.6K | — | 3.6K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -1.40M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.